Site icon Duncan Bucknell

Pharma & Biotech GWiR 16 January 2009 from IP Think Tank

Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

 
Highlights this week included:

India: Discussion of Delhi High Court’s ex parte order in BMS v Hetero – Drug controllers to analyse patents while patent controllers analyse efficacy?; A setback to Indian drug industry? (IP Think Tank) (GenericsWeb)

Kenya: India up in arms over Kenya’s anti-counterfeit bill (Afro-IP)

 
 
General

Pharmaceutical patent linkage by unusual means – IP Think Tank podcast 12 Jan 09 (IP Think Tank)

EU: European Commission pharma sector inquiry – preliminary report (The SPC Blog)

India: Drug controllers to analyse patents while patent controllers analyse efficacy? (IP Think Tank)

India: Ex parte order to Bristol-Myers setback to Indian drug industry?: BMS v Hetero (GenericsWeb)

India: Adding innovation to Ayurveda! (Spicy IP)

Kenya: India up in arms over Kenya’s anti-counterfeit bill (Afro-IP)

UK: Will Biotechnology and Biological Sciences Research Council’s Industrial Impact Fellows make an industrial impact? (IP finance)

US: Medarex, Eurand and Alexion file actions against Director Dudas seeking revised patent term adjustment determinations (Patent Docs)

US: Kubin panel questions motivation behind reversal in new Written Description Training Materials (Patent Docs)

US: The obviousness of DNA – Federal Circuit heard oral argument for In re Kubin last week (Patent Docs)

 
Products

Antara (Fenofibrate) – US: Oscient and Ethypharm file patent infringement suit against Lupin over Antara (Law360) (GenericsWeb)

Clobex (Clobetasol propionate) – US: Galderma files patent infringement suit against Paddock Laboratories to block generic Clobex (Law360)

Effexor (Venlafaxine) – US: Wyeth files patent infringement suit against Torrent Pharmaceuticals over its bid to produce generic Effexor (Law360)

Femcon Fe (Norethindrone, Ethinyl estradiol, Ferrous fumarate) – US: Warner Chilcott and Watson Pharmaceuticals announce licence agreements on Loestrin and Femcon, settling patent litigation (SmartBrief) (Law360) (GenericsWeb)

Focalin (Dexmethylphenidate) – US: Wilful infringement claims dismissed in two actions filed by Celgene and Novartis to block generic Focalin (Law360)

Hytrin (Terazosin) – US: Court of Appeal for the Ninth Circuit revives Hytrin antitrust case between Kaiser Foundation Health Plan and Abbott Laboratories (Law360) (Hal Wegner)

Loestrin 24 Fe (Norethindrone acetate, Ethinyl estradiol, USP, Ferrous Fumarate) – US: US: Warner Chilcott and Watson Pharmaceuticals announce licence agreements on Loestrin and Femcon, settling patent litigation (SmartBrief) (Law360)

Pataday (Olopatadine) – US: Alcon files patent infringement suit against Barr Laboratories over its generic Pataday ANDA submission (Law360)

Perforomist (Formoterol) – US: PTO issues Mylan’s subsidiary Dey LP three additional patents protecting Perforomist (SmartBrief)

Seroquel (Quetiapine) – US: AstraZeneca files patent infringement suit against Biovail and subsidiaries over Seroquel (Law360)

Solodyn (Minocycline) – US: Medicis Pharmaceutical sues Mylan, Barr, Sandoz over ANDAs for Solodyn (Law360) (GenericsWeb)

 

Exit mobile version